Lee Soyun, Jo Hyesu, Fond Guillaume, Boyer Laurent, Smith Lee, Hajek André, Yon Dong Keon
Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.
Eur J Clin Pharmacol. 2025 Jun 6. doi: 10.1007/s00228-025-03851-5.
This study aims to investigate the signal detection between the use of finasteride and dutasteride and the occurrence of suicidality, including suicidal ideation, attempts, and completed suicide, as well as the development of depression.
This study utilized data from a global pharmacovigilance database encompassing over 35 million adverse event reports from more than 140 countries. Suicidality and depression were defined by MedDRA terms version 26.0. To analyze the data, two well-established pharmacovigilance indicators were applied: the information component (IC) and the reporting odds ratio (ROR).
A total of 395 and 1299 reports of suicidality and depression, respectively, were identified in signal detection with finasteride and dutasteride. Reporting trends showed that cases first emerged in 1992, with a notable increase after 2010. The main analysis identified signal detections between finasteride use and both suicidality (ROR, 7.28 [95% CI, 6.57-8.06]; IC, 2.82 [IC, 2.65]) and depression (ROR, 28.18 [95% CI, 26.57-29.89]; IC, 4.68 [IC, 4.58]), whereas dutasteride showed no significant signal for suicidality and a weaker signal with depression (ROR, 3.23 [95% CI, 2.61-4.00]; IC, 1.66 [IC, 1.30]). In subgroup analysis, younger individuals (18-44 years) had particularly strong signals for suicidality (IC, 3.54 [IC, 3.27]), and depression (IC, 5.25 [IC, 5.05]) associated with finasteride, suggesting a heightened susceptibility in this age group. The time to onset of suicidality and depression was predominantly reported after 3 months of drug administration, with suicidality occurring at an average of 114.92 days and depression at 93.31 days.
Although our study does not imply causality, this findings suggest a statistically significant disproportionality in reports of suicidality and depression associated with finasteride use and increased signal risks of suicidality and depression highlighting the need for further large-scale epidemiological studies to confirm these findings and investigate the underlying mechanisms.
本研究旨在调查非那雄胺和度他雄胺的使用与自杀行为(包括自杀意念、自杀未遂和自杀死亡)的发生以及抑郁症发展之间的信号检测情况。
本研究利用了一个全球药物警戒数据库的数据,该数据库包含来自140多个国家的超过3500万份不良事件报告。自杀行为和抑郁症由MedDRA术语版本26.0定义。为了分析数据,应用了两个成熟的药物警戒指标:信息成分(IC)和报告比值比(ROR)。
在非那雄胺和度他雄胺的信号检测中,分别共识别出395份和1299份自杀行为和抑郁症报告。报告趋势显示,病例于1992年首次出现,2010年后显著增加。主要分析确定了非那雄胺使用与自杀行为(ROR,7.28 [95% CI,6.57 - 8.06];IC,2.82 [IC,2.65])和抑郁症(ROR,28.18 [95% CI,26.57 - 29.89];IC,4.68 [IC,4.58])之间的信号检测,而度他雄胺在自杀行为方面未显示出显著信号,在抑郁症方面信号较弱(ROR,3.23 [95% CI,2.61 - 4.00];IC,1.66 [IC,1.30])。在亚组分析中,年轻个体(18 - 44岁)与非那雄胺相关的自杀行为(IC,3.54 [IC,3.27])和抑郁症(IC,5.25 [IC,5.05])信号尤为强烈,表明该年龄组易感性较高。自杀行为和抑郁症的发病时间主要报告在用药3个月后,自杀行为平均发生在114.92天,抑郁症平均发生在93.31天。
尽管我们的研究并不意味着存在因果关系,但这些发现表明,与非那雄胺使用相关的自杀行为和抑郁症报告在统计学上存在显著的不成比例,以及自杀行为和抑郁症的信号风险增加,这凸显了需要进一步进行大规模流行病学研究以证实这些发现并调查潜在机制。